Jessica Sitler
Acute Care · Youngstown, OHNPI 1205489382
Payments from drug & device makers
Across 13 payments — averaging $26.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$117
- Astellas Pharma US Inc$52
- Myovant Sciences Inc.$46
- Convatec Inc.$38
- Davol Inc.$33
- Blue Earth Diagnostics$26
- plus $37 from 2 others
What the payments were for
- Food & beverage$27378%
- Education$7622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 5 | $117 |
| Astellas Pharma US Inc | 1 | $52 |
| Myovant Sciences Inc. | 2 | $46 |
| Convatec Inc. | 1 | $38 |
| Davol Inc. | 1 | $33 |
| Blue Earth Diagnostics | 1 | $26 |
| Urogen Pharma, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $13 |
How this compares
$349 in reported general payments places this provider in the 55th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 145 | $91,865 |
| MyrbetriqMirabegron | 117 | $80,101 |
| Tamsulosin Hcl | 462 | $6,032 |
| NitrofurantoinNitrofurantoin Macrocrystal | 172 | $3,604 |
| Finasteride | 218 | $2,776 |
| Tolterodine Tartrate ErTolterodine Tartrate | 39 | $2,580 |
| Trospium Chloride | 14 | $1,966 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 67 | $1,506 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 113 | $1,140 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,129 |
| Oxybutynin Chloride ErOxybutynin Chloride | 57 | $1,000 |
| Doxycycline Hyclate | 134 | $816 |
| Solifenacin Succinate | 17 | $802 |
| CefuroximeCefuroxime Axetil | 40 | $390 |
| Dutasteride | 23 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $117 | $91,865145 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $80,101117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,101 acute care providers in Ohio.
Other acute care in Youngstown
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Holly McKibbenColumbus$23K
- Jody HussBlue Ash$13K
- Julie LurieCincinnati$13K
- Susan BrooksMount Vernon$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.